Skip to content

Assessing ion-channel dysfunction in ALS using surface-EMG and high-resolution ultrasound

Assessing ion-channel dysfunction in ALS using surface-EMG and high-resolution ultrasound - Ion-channel dysfunction in ALS

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
NL-OMON
Registry ID
NL-OMON55763
Enrollment
400
Registered
2019-12-11
Start date
2020-07-27
Completion date
Unknown
Last updated
2024-11-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

amyotrophic lateral sclerosis neuromuscular diseases

Interventions

None listed

Sponsors

Universitair Medisch Centrum Utrecht
Lead Sponsor

Eligibility

Age
18 Years to 99 Years

Inclusion criteria

Inclusion criteria: - Age >= 18 years - Written informed consent - Patients with suspected MND and who are referred for an EMG, healthy controls and family members of patients with MND who have an established genetic mutation

Exclusion criteria

Exclusion criteria: - Age

Design outcomes

Primary

MeasureTime frame
1. Axonal excitability-variables of the median nerve motor axons at the wrist to determine ion channel dysfunction. Each excitability test consists of 4 subtests, including: (i) Latent addition and strength-duration time constant (SDTC) reflects activation of persistent Na-channels, (ii) threshold electrotonus reflects resting membrane potential, (iii) current-voltage (I/V) relationship reflects activity of slow K-channels and HCN-channels, (iv) recovery cycle reflects transient Na-channel inactivation. 2. Clinical parameters of functional state (ALSFRS-R questionnaire), survival and/or time to assisted ventilation.

Secondary

MeasureTime frame
1. Sonographic variables (amount of fasciculations - in median nerve innervated muscles, and nerve size - cross-sectional area of median nerve at forearm and upper arm level) on ultrasound imaging. 2. Demographic data and patient characteristics (age, gender, weight, medical history, disease duration), and results from routine genetic testing (sporadic or familial ALS with genetic mutations e.g. C9orf72). 3. Data from routine EMG and CMAP scan based examination (electromyographic features of lower motor neurone involvement).

Countries

Netherlands

Outcome results

None listed

Source: NL-OMON (via WHO ICTRP)